Evidence map›Paper›PMID 29736302›Full record

ReviewBone research2018

Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.

Qiang Guo, Yuxiang Wang, Dan Xu, Johannes Nossent, Nathan J Pavlos, Jiake Xu

3 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 772 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
772citing papers in PubMed, 9 pooled it
109.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05788705 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Evaluation of the Efficacy of Natural JAK_ STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis as a Complementary Medicine

TypeinterventionalSponsorAdel A.GomaaRan2023 to 2025Enrolled75ConditionsRheumatoid ArthritisArms"apigenin" and "glycyrrhizin", "glycyrrhizin" and "boswellic acid", "placebo"
NCT06641128 phase4not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Clinical Study Evaluating the Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

TypeinterventionalSponsorTanta UniversityRan2024 to 2025Enrolled44ConditionsRheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse ReactionArmsMTX SC or IM, Empagliflozin 25mg tab
NCT06724952 phase4not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Clinical Study Evaluating Anti Rheumatic Activity and The Role of Silymarin in Attenuating Methotrexate Toxicity in Patients With Rheumatoid Arthritis

TypeinterventionalSponsorTanta UniversityRan2024 to 2025Enrolled44ConditionsRheumatoid Arthritis (RA)ArmsMTX S.C or IM and Silymarin 140 mg tab, MTX S.C or IM
3 · Its place in the literature

Who cites it

772 citing papers in PubMed, 9 syntheses or guidelines pooled it, 1,723 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

712 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Qiang Guo1Department of Spine Surgery, Xiangya Hospital, Central South University, No. 87, Xiangya Road, 410008 Changsha, China.
Yuxiang Wang1Department of Spine Surgery, Xiangya Hospital, Central South University, No. 87, Xiangya Road, 410008 Changsha, China.
Dan Xu2School of Biomedical Sciences, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia 6009 Australia.
Johannes NossentMusculoskeletal Health Network, Department of Health WA, 189 Royal Street, East Perth, WA 6004 Australia.
Nathan J Pavlos2School of Biomedical Sciences, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia 6009 Australia.
Jiake Xu2School of Biomedical Sciences, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia 6009 Australia.
University of Western Australia · AUXiangya Hospital Central South University · CNHealth Net · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our  understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA.

Identifiers

PMID29736302
PMCPMC5920070
OpenAlexW2803973097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.